Global Burden of Multiple Myeloma
JAMA Oncology2018Vol. 4(9), pp. 1221–1221
Citations Over TimeTop 1% of 2018 papers
Andrew J. Cowan, Christine A. Allen, Aleksandra Barać, Huda Basaleem, Isabela M. Benseñor, María Paula Curado, Kyle J Foreman, Rahul Gupta, James Harvey, Hung Chak Ho, Mihajlo Jakovljević, Yousef Khader, Shai Linn, Deepesh Lad, LG Mantovani, Vuong Minh Nong, Ali H. Mokdad, Mohsen Naghavi, Maarten J. Postma, Gholamreza Roshandel, Katya Anne Shackelford, Mekonnen Sisay, Cuong Tat Nguyen, Tung Thanh Tran, Bach Xuan Tran, Kingsley Nnanna Ukwaja, Dan J. Stein, Elisabete Weiderpass, Edward N. Libby, Christina Fitzmaurice
Abstract
Incidence of MM is highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities for MM are to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity in myeloma incidence.
Related Papers
- → Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma(2012)27 cited
- Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.(2010)
- → Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma(2007)29 cited
- → Proteasome Inhibitors in Treatment of Multiple Myeloma(2013)3 cited
- Effect of Bortezomib on serum cystatin-C in multiple myeloma(2011)